Published in Volume
96, Issue 5 (November 1995)
J Clin Invest. 1995;96(5):2195–2203.
doi:10.1172/JCI118274.
Copyright ©
1995, The American Society for
Clinical Investigation.
Research Article
Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis.
M K Racke, D E Scott, L Quigley, G S Gray, R Abe, C H June and P J Perrin
Neuroimmunology Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Maryland 20892.
Published November 1995
The activation and differentiation of T cells require both antigen/MHC recognition and costimulatory signals. The present studies examined the role of B7-1 (CD80) and B7-2 (CD86) costimulation in the prototypic autoimmune disorder, experimental allergic encephalomyelitis (EAE). In adoptively transferred EAE, in vitro activation of myelin basic protein (MBP)-specific lymph node cells was inhibited by the combination of anti-CD80 plus anti-CD86, but not individually. However, in actively induced disease, one injection of anti-CD80 significantly reduced disease, while anti-CD86 exacerbated disease. Interestingly, one injection of CTLA-4Ig suppressed disease, while multiple injections resulted in enhanced disease. Thus, the costimulation provided by B7-1 molecules appears to be important for the development of encephalitogenic T cells. The enhanced disease caused by multiple injections of CTLA-4Ig or a single injection of anti-CD86 suggests an inhibitory function for CD86 interaction with its counterreceptors CD28 and CTLA-4 in EAE. Alternatively, these results are consistent with an essential timing requirement for the coordinated interaction of B7 and CD28 family receptors, and that disruption of this critical timing can have opposing results on the outcome of an immune response.
Browse pages
Click on an image below to see the page. View
PDF of the complete article